Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 16/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890441 | 0.93 | AOC3 (0.58) | AOC3MAOBADRA2BSLC6A4SLC6A3 | |
| SCHEMBL14281006 | 0.86 | AOC3 (0.61) | AOC3MAOBADRA2BSLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4880230 | 0.85 | AOC3 (0.60) | AOC3MAOBADRA2BSLC6A4SLC6A3 | |
| SCHEMBL14281002 | 0.80 | AOC3 (0.63) | AOC3MAOBKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4880264 | 0.79 | AOC3 (0.61) | AOC3MAOBKMT2ASMN1; SMN2 | |
| SCHEMBL14281004 | 0.78 | AOC3 (0.61) | AOC3MAOBADRA2BSLC6A4SLC6A3 | |
| SCHEMBL4889744 | 0.78 | AOC3 (0.58) | AOC3MAOBADRA2BSLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4888620 | 0.78 | AOC3 (0.60) | AOC3MAOBADRA2BSLC6A4SLC6A3 | |
| SCHEMBL4890676 | 0.77 | AOC3 (0.45) | AOC3MAOBADRA2BSLC6A4SLC6A3 | |
| SCHEMBL3934166 | 0.75 | AOC3 (0.85) | AOC3MAOBKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1791835-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006028269-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 IHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | AOC3 163/4885MAOB 1224/4885ADRA2B 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.